NASDAQ:SRDX - SurModics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $45.65 -1.91 (-4.02 %) (As of 03/19/2019 04:00 PM ET)Previous Close$47.56Today's Range$44.86 - $46.7852-Week Range$34.06 - $82.35Volume9,151 shsAverage Volume97,171 shsMarket Capitalization$615.36 millionP/E Ratio93.20Dividend YieldN/ABeta1.32 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota. Receive SRDX News and Ratings via Email Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:SRDX Previous Symbol CUSIP86887310 CIK924717 Webwww.surmodics.com Phone952-500-7000Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.26Price-To-Earnings Trailing P/E Ratio93.20 Forward P/E Ratio304.33 P/E Growth34.74 Sales & Book Value Annual Sales$81.34 million Price / Sales7.57 Cash Flow$0.8638 per share Price / Cash Flow52.85 Book Value$8.13 per share Price / Book5.62Profitability EPS (Most Recent Fiscal Year)$0.49 Net Income$-4,450,000.00 Net Margins-1.84% Return on Equity6.37% Return on Assets4.43%Miscellaneous EmployeesN/A Outstanding Shares13,480,000Market Cap$615.36 million Next Earnings Date5/1/2019 (Estimated) OptionableOptionable SurModics (NASDAQ:SRDX) Frequently Asked Questions What is SurModics' stock symbol? SurModics trades on the NASDAQ under the ticker symbol "SRDX." How were SurModics' earnings last quarter? SurModics, Inc. (NASDAQ:SRDX) issued its quarterly earnings data on Wednesday, January, 30th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.00 by $0.12. The business had revenue of $22.24 million for the quarter, compared to analyst estimates of $18.90 million. SurModics had a positive return on equity of 6.37% and a negative net margin of 1.84%. View SurModics' Earnings History. When is SurModics' next earnings date? SurModics is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for SurModics. What guidance has SurModics issued on next quarter's earnings? SurModics issued an update on its FY 2019 earnings guidance on Wednesday, January, 30th. The company provided EPS guidance of $0.02-0.22 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.09. The company issued revenue guidance of $94-97 million, compared to the consensus revenue estimate of $93.76 million. What price target have analysts set for SRDX? 3 equities research analysts have issued 12 month price targets for SurModics' shares. Their predictions range from $74.00 to $90.00. On average, they expect SurModics' share price to reach $80.3333 in the next year. This suggests a possible upside of 76.0% from the stock's current price. View Analyst Price Targets for SurModics. What is the consensus analysts' recommendation for SurModics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurModics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SurModics. What are Wall Street analysts saying about SurModics stock? Here are some recent quotes from research analysts about SurModics stock: 1. Needham & Company LLC analysts commented, "SRDX has embarked upon its whole-product solutions" strategy and has a number of medical devices in development or commercialization that it intends to sell through distribution partners. The potential revenue from these products varies widely; to use a baseball analogy, we think these product opportunities range from potential singles" (e.g. its 510(k) products) to potential home runs" (e.g. its drug-coated balloons or DCBs). Given the multiple moving parts of the SRDX story, we thought it would be worthwhile to conduct a “sum-of-the-parts” (SOTP) analysis. Our SOTP analysis implies that SRDX’s 2020E enterprise value should be ~$1.0B, or ~ $74 per SRDX share. Given this, we raise our price target to $74 from $69 and reiterate our Buy rating. Please contact us or your Needham sales person for our SRDX SOTP spreadsheet." (2/21/2019) 2. According to Zacks Investment Research, "Surmodics has outperformed the industry in a year’s time. The company continues to gain from its core Medical Device and IVD units and the trend is expected to continue in fiscal 2019 as well. Management is also optimistic about the agreement with MedTech behemoth Abbott for commercialization of its SurVeil drug-coated balloon. Surmodics also expects to complete the TRANSCEND clinical study enrollment by fiscal 2019. Management is hopeful about its new product AVess. On the flip side, a significant year-over-year decline in earnings per share in recent times is worrisome. Surging operating expenses and operating losses at the Medical Device unit are likely to keep the company’s margins under pressure. Surmodics’ drug-coated balloons also face stiff competition in the niche space." (1/14/2019) 3. Barrington Research analysts commented, "We are now modeling adjusted FY/18 adjusted EPS of $(0.02) and revenue of $78.4 million. DCB: Patient enrollment for the company’s TRANSCEND pivotal clinical trial continues and about half of U.S.-based clinical sites have now been activated. As a reminder, the trial to treat peripheral artery disease in the upper leg will be randomized and is expected to include 446 patients at up to 60 clinical sites in the U.S. and 18 sites in Europe. It will feature a head-to-head comparison with a competitor’s already commercialized drug-coated balloon product 510(k) products: Surmodics has now received FDA approvals for its first three 510(k) products (two balloon catheters and a microcatheter). Management remains hopeful that it will enter into partnership for all three products over the next two to four quarters Recommendation: We are maintaining our OUTPERFORM investment rating on SRDX shares. Our new price target is $43, up from our previous $38." (5/3/2018) Has SurModics been receiving favorable news coverage? Press coverage about SRDX stock has trended neutral this week, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. SurModics earned a daily sentiment score of 0.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days. Who are some of SurModics' key competitors? Some companies that are related to SurModics include Cantel Medical (CMD), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Atrion (ATRI), Cardiovascular Systems (CSII), Nevro (NVRO), K2M Group (KTWO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Cryolife (CRY), Luminex (LMNX), Orthofix Medical (OFIX), Intersect ENT (XENT) and Cerus (CERS). What other stocks do shareholders of SurModics own? Based on aggregate information from My MarketBeat watchlists, some companies that other SurModics investors own include NVIDIA (NVDA), Exelixis (EXEL), Intel (INTC), Micron Technology (MU), Zoetis (ZTS), Supernus Pharmaceuticals (SUPN), Adobe (ADBE), Galmed Pharmaceuticals (GLMD), Uniqure (QURE) and Portola Pharmaceuticals (PTLA). Who are SurModics' key executives? SurModics' management team includes the folowing people: Mr. Gary R. Maharaj, CEO, Pres & Director (Age 56)Mr. Timothy J. Arens, Chief Financial Officer (Age 52)Mr. Bryan K. Phillips, Sr. VP of Legal, HR & Information Technology, Gen. Counsel and Sec. (Age 48)Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 53)Mr. Gregg S. Sutton, VP of R&D - Medical Devices (Age 59) Who are SurModics' major shareholders? SurModics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.64%), Trigran Investments Inc. (5.90%), Dimensional Fund Advisors LP (4.60%), Dimensional Fund Advisors LP (4.60%), Royce & Associates LP (2.34%) and Acadian Asset Management LLC (1.86%). Company insiders that own SurModics stock include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Lisa Wipperman Heine, Susan E Knight and Timothy J Arens. View Institutional Ownership Trends for SurModics. Which institutional investors are selling SurModics stock? SRDX stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Royce & Associates LP, Prudential Financial Inc., Assenagon Asset Management S.A., Teton Advisors Inc., Barclays PLC and Castleark Management LLC. Company insiders that have sold SurModics company stock in the last year include Bryan K Phillips, Charles W Olson, Gary R Maharaj, Gregg S Sutton, Jose H Bedoya, Joseph J Stich, Lisa Wipperman Heine, Susan E Knight and Timothy J Arens. View Insider Buying and Selling for SurModics. Which institutional investors are buying SurModics stock? SRDX stock was acquired by a variety of institutional investors in the last quarter, including Trigran Investments Inc., American Century Companies Inc., BlackRock Inc., QS Investors LLC, Bank of America Corp DE, Rhumbline Advisers, Mackenzie Financial Corp and Mackay Shields LLC. View Insider Buying and Selling for SurModics. How do I buy shares of SurModics? Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is SurModics' stock price today? One share of SRDX stock can currently be purchased for approximately $45.65. How big of a company is SurModics? SurModics has a market capitalization of $615.36 million and generates $81.34 million in revenue each year. The company earns $-4,450,000.00 in net income (profit) each year or $0.49 on an earnings per share basis. What is SurModics' official website? The official website for SurModics is http://www.surmodics.com. How can I contact SurModics? SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected] MarketBeat Community Rating for SurModics (NASDAQ SRDX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 250 (Vote Outperform)Underperform Votes: 211 (Vote Underperform)Total Votes: 461MarketBeat's community ratings are surveys of what our community members think about SurModics and other stocks. Vote "Outperform" if you believe SRDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What is a capital gain?